Clinical trial
Recombinant Human Relaxin (rhRlx) in Pregnant Women Scheduled for Induction of…
NCT00259103 · Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies, Industry · Completed
Key facts
| NCT number | NCT00259103 |
|---|---|
| Title | Recombinant Human Relaxin (rhRlx) in Pregnant Women Scheduled for Induction of Labor |
| Official title | A Phase II Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Safety, Pharmacokinetics and Efficacy of Intravenous Recombinant Human Relaxin (rhRlx) in Pregnant Women Scheduled for Induction of Labour |
| Lead sponsor | Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Labor, Induced |
| Intervention type | Drug |
| Interventions | Serelaxin, Placebo |
| Enrollment | 72 |
| Start date | Nov 1, 2005 |
| Primary completion | Oct 1, 2006 |
| Completion | Oct 1, 2006 |
| First posted | Nov 29, 2005 |
| Last update posted | May 7, 2014 |
| Countries | Russia |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: